ReviewFrontiers in endocrinology2026
INSL3: an informative testis biomarker for assessing the HPG axis in men.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The male hypothalamo-pituitary-gonadal (HPG) axis is an integrated endocrine system linking hypothalamic GnRH secretion, pituitary gonadotropins (LH and FSH), Leydig cell steroidogenesis, Sertoli cell function, and spermatogenesis. While conventional parameters such as testosterone or LH may be subject to high biological variance due to their pulsatile mode of secretion and multiple stress-related or environmental influences, the Leydig-cell-secreted peptide insulin-like peptide 3 (INSL3) offers a robust and constitutive alternative reflecting Leydig cell number, differentiation status, and long-term functional capacity. This narrative review considers INSL3 across the male life course in relation to other components of the HPG axis, including in fetal development, minipuberty, pubertal development, and male aging. It shows how measuring INSL3 offers important granularity in understanding issues such as the effects of environmental endocrine disruption, childhood, and lifestyle influences on pubertal development as well as on adult Leydig cell capacity, hypogonadism, and age-related morbidity. The presented evidence suggests that INSL3 will prove to be a useful biomarker for the HPG axis in adult life, though the reference range in healthy adults is quite large for yet unknown reasons; associations with BMI as well as early childhood and adolescent influences are described. While INSL3 reflects the GnRH-LH-testosterone arm of the HPG axis and is normally not directly linked to the spermatogenic compartment and male fertility, some studies do suggest a supportive relationship which merits further research. Similarly, other functions of INSL3 in men also remain underexplored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.